We are live on ! Find out more
ARIA

Ariad Pharmaceuticals Inc
ARIA

Delisted

ARIA was delisted on the 15th of February, 2017.

166 hedge funds and large institutions have $801M invested in Ariad Pharmaceuticals Inc in 2013 Q4 according to their latest regulatory filings, with 46 funds opening new positions, 51 increasing their positions, 58 reducing their positions, and 88 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more funds holding in top 10

Funds holding in top 10: 24 (+2)

12% less repeat investments, than reductions

Existing positions increased: 51 | Existing positions reduced: 58

20% less funds holding

Funds holding: 208166 (-42)

26% less call options, than puts

Call options by funds: $35.5M | Put options by funds: $48.1M

48% less first-time investments, than exits

New positions opened: 46 | Existing positions closed: 88

72% less capital invested

Capital invested by funds: $2.85B → $801M (-$2.05B)

Holders
166
Holders Change
-42
Holders Change %
-20.19%
% of All Funds
4.82%
Holding in Top 10
4
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+100%
% of All Funds
0.12%
New
46
Increased
51
Reduced
58
Closed
88
Calls
$35.5M
Puts
$48.1M
Net Calls
-$12.6M
Net Calls Change
+$3.73M
Name Holding Trade Value Shares
Change
Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$116M -$13.6M -2,522,084 -13%
SCM
2
Sarissa Capital Management
Connecticut
$81.8M +$64.8M +12,000,000 New
Vanguard Group
3
Vanguard Group
Pennsylvania
$70.5M +$2.05M +379,541 +4%
Franklin Resources
4
Franklin Resources
California
$49.7M -$4.46M -826,683 -10%
State Street
5
State Street
Massachusetts
$43.3M +$14.9M +2,755,365 +77%
CCM
6
Camber Capital Management
Massachusetts
$35.8M +$28.3M +5,250,000 New
BIT
7
BlackRock Institutional Trust
California
$32.8M +$1.93M +356,687 +8%
BFA
8
BlackRock Fund Advisors
California
$24.6M -$667K -123,460 -3%
Adage Capital Partners
9
Adage Capital Partners
Massachusetts
$23.9M +$13.1M +2,429,248 +227%
PAI
10
Palo Alto Investors
California
$23.5M +$18.6M +3,441,324 New
Susquehanna International Group
11
Susquehanna International Group
Pennsylvania
$18.7M +$12M +2,215,605 +422%
PC
12
PointState Capital
New York
$15M +$10.8M +2,000,000 +1,000%
Norges Bank
13
Norges Bank
Norway
$14.5M -$2.36M -436,681 -17%
SFM
14
Soros Fund Management
New York
$13.3M +$10.5M +1,950,000 New
OM
15
Opaleye Management
Massachusetts
$11.9M +$9.02M +1,670,000 New
Barclays
16
Barclays
United Kingdom
$11.6M +$9.33M +1,727,814 +868%
AQR Capital Management
17
AQR Capital Management
Connecticut
$10.2M +$7.63M +1,413,174 +1,768%
Millennium Management
18
Millennium Management
New York
$10M +$4.23M +784,015 +115%
BB
19
BB Biotech
Switzerland
$9.46M -$12.4M -2,301,900 -62%
GAI
20
General American Investors
New York
$8.18M +$4.1M +760,000 +173%
GPCM
21
Granite Point Capital Management
Massachusetts
$8.18M +$6.48M +1,200,000 New
Nomura Holdings
22
Nomura Holdings
Japan
$7.32M +$4.73M +875,303 +436%
Ameriprise
23
Ameriprise
Minnesota
$7.27M -$23.7M -4,391,098 -80%
AGCJ
24
Alden Global Capital (Jersey)
Jersey
$7.2M +$5.7M +1,055,900 New
Group One Trading
25
Group One Trading
Illinois
$6.67M +$4.38M +810,967 +483%

ARIA Hedge Fund Activity: Q4 2013 in Review

166 of the 3,445 institutional investors tracked by Wall St. Rank reported a position in Ariad Pharmaceuticals Inc (ARIA) for Q4 2013, worth a combined $801M — down 72% from $2.85B a quarter earlier.

Sellers outnumbered buyers: 88 funds closed out of ARIA and 46 opened new positions — a net loss of 42 holders — while 58 trimmed existing stakes and 51 added.

The largest buyer was Camber Capital Management, opening a new position worth an estimated $28.3M. The largest seller was Waddell & Reed Financial, exiting entirely with an estimated $106M sold.

  • 166 institutional investors held Ariad Pharmaceuticals Inc (ARIA) as of Q4 2013, down from 208 in Q3 2013.
  • Funds reported $801M of Ariad Pharmaceuticals Inc stock for Q4 2013, down 72% quarter-over-quarter.
  • 46 funds opened new Ariad Pharmaceuticals Inc positions in Q4 2013 and 88 closed out, a net change of -42 holders.
  • The largest Ariad Pharmaceuticals Inc buyer in Q4 2013 was Camber Capital Management, an estimated $28.3M added.
  • The largest Ariad Pharmaceuticals Inc seller in Q4 2013 was Waddell & Reed Financial, an estimated $106M sold.

Based on aggregated 13F filings for Q4 2013.